Selected research
Industry Research
Sustained-release Medicine Industry Research Report 2026
Market perspective
The global Sustained-release Medicine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Sustained-release Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Sustained-release Medicine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Sustained-release Medicine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Sustained-release Medicine include Zhuhai Rundu Pharmaceutical, Endo Pharmaceuticals, Takeda, Shanghai Shyndec Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Pfizer and China Res Double-Crane, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Sustained-release Medicine market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Sustained-release Medicine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sustained-release Medicine Market by Company
Zhuhai Rundu Pharmaceutical
Endo Pharmaceuticals
Takeda
Shanghai Shyndec Pharmaceutical
Sanofi
Johnson & Johnson
Novartis
Pfizer
China Res Double-Crane
Bayer
AbbVie
AstraZeneca
Collegium Pharmaceutical, Inc
Sustained-release Medicine Segment by Type
Original Ground Medicine
Generic Medicine
Sustained-release Medicine Segment by Application
Hospital
Drugstore
Other
Sustained-release Medicine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained-release Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained-release Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained-release Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Sustained-release Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Original Ground Medicine
- Generic Medicine
Applications
- Hospital
- Drugstore
- Other
Companies covered
- Zhuhai Rundu Pharmaceutical
- Endo Pharmaceuticals
- Takeda
- Shanghai Shyndec Pharmaceutical
- Sanofi
- Johnson & Johnson
- Novartis
- Pfizer
- China Res Double-Crane
- Bayer
- AbbVie
- AstraZeneca
- Collegium Pharmaceutical, Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Sustained-release Medicine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Original Ground Medicine
- 2.2.3 Generic Medicine
- 2.3 Sustained-release Medicine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Drugstore
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Sustained-release Medicine Breakdown Data by Type
- 3.1 Global Sustained-release Medicine Historic Market Size by Type (2021-2026)
- 3.2 Global Sustained-release Medicine Forecasted Market Size by Type (2027-2032)
4 Sustained-release Medicine Breakdown Data by Application
- 4.1 Global Sustained-release Medicine Historic Market Size by Application (2021-2026)
- 4.2 Global Sustained-release Medicine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Sustained-release Medicine Market Perspective (2021-2032)
- 5.2 Global Sustained-release Medicine Growth Trends by Region
- 5.2.1 Global Sustained-release Medicine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Sustained-release Medicine Historic Market Size by Region (2021-2026)
- 5.2.3 Sustained-release Medicine Forecasted Market Size by Region (2027-2032)
- 5.3 Sustained-release Medicine Market Dynamics
- 5.3.1 Sustained-release Medicine Industry Trends
- 5.3.2 Sustained-release Medicine Market Drivers
- 5.3.3 Sustained-release Medicine Market Challenges
- 5.3.4 Sustained-release Medicine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Sustained-release Medicine Players by Revenue
- 6.1.1 Global Top Sustained-release Medicine Players by Revenue (2021-2026)
- 6.1.2 Global Sustained-release Medicine Revenue Market Share by Players (2021-2026)
- 6.2 Global Sustained-release Medicine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Sustained-release Medicine Head Office and Area Served
- 6.4 Global Sustained-release Medicine Players, Product Type & Application
- 6.5 Global Sustained-release Medicine Manufacturers Established Date
- 6.6 Global Sustained-release Medicine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Sustained-release Medicine Market Size (2021-2032)
- 7.2 North America Sustained-release Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Sustained-release Medicine Market Size by Country (2021-2026)
- 7.4 North America Sustained-release Medicine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Sustained-release Medicine Market Size (2021-2032)
- 8.2 Europe Sustained-release Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Sustained-release Medicine Market Size by Country (2021-2026)
- 8.4 Europe Sustained-release Medicine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Sustained-release Medicine Market Size (2021-2032)
- 9.2 Asia-Pacific Sustained-release Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Sustained-release Medicine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Sustained-release Medicine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Sustained-release Medicine Market Size (2021-2032)
- 10.2 South America Sustained-release Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Sustained-release Medicine Market Size by Country (2021-2026)
- 10.4 South America Sustained-release Medicine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Sustained-release Medicine Market Size (2021-2032)
- 11.2 Middle East & Africa Sustained-release Medicine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Sustained-release Medicine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Sustained-release Medicine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Zhuhai Rundu Pharmaceutical
- 12.1.1 Zhuhai Rundu Pharmaceutical Company Information
- 12.1.2 Zhuhai Rundu Pharmaceutical Business Overview
- 12.1.3 Zhuhai Rundu Pharmaceutical Revenue in Sustained-release Medicine Business (2021-2026)
- 12.1.4 Zhuhai Rundu Pharmaceutical Sustained-release Medicine Product Portfolio
- 12.1.5 Zhuhai Rundu Pharmaceutical Recent Developments
- 12.2 Endo Pharmaceuticals
- 12.2.1 Endo Pharmaceuticals Company Information
- 12.2.2 Endo Pharmaceuticals Business Overview
- 12.2.3 Endo Pharmaceuticals Revenue in Sustained-release Medicine Business (2021-2026)
- 12.2.4 Endo Pharmaceuticals Sustained-release Medicine Product Portfolio
- 12.2.5 Endo Pharmaceuticals Recent Developments
- 12.3 Takeda
- 12.3.1 Takeda Company Information
- 12.3.2 Takeda Business Overview
- 12.3.3 Takeda Revenue in Sustained-release Medicine Business (2021-2026)
- 12.3.4 Takeda Sustained-release Medicine Product Portfolio
- 12.3.5 Takeda Recent Developments
- 12.4 Shanghai Shyndec Pharmaceutical
- 12.4.1 Shanghai Shyndec Pharmaceutical Company Information
- 12.4.2 Shanghai Shyndec Pharmaceutical Business Overview
- 12.4.3 Shanghai Shyndec Pharmaceutical Revenue in Sustained-release Medicine Business (2021-2026)
- 12.4.4 Shanghai Shyndec Pharmaceutical Sustained-release Medicine Product Portfolio
- 12.4.5 Shanghai Shyndec Pharmaceutical Recent Developments
- 12.5 Sanofi
- 12.5.1 Sanofi Company Information
- 12.5.2 Sanofi Business Overview
- 12.5.3 Sanofi Revenue in Sustained-release Medicine Business (2021-2026)
- 12.5.4 Sanofi Sustained-release Medicine Product Portfolio
- 12.5.5 Sanofi Recent Developments
- 12.6 Johnson & Johnson
- 12.6.1 Johnson & Johnson Company Information
- 12.6.2 Johnson & Johnson Business Overview
- 12.6.3 Johnson & Johnson Revenue in Sustained-release Medicine Business (2021-2026)
- 12.6.4 Johnson & Johnson Sustained-release Medicine Product Portfolio
- 12.6.5 Johnson & Johnson Recent Developments
- 12.7 Novartis
- 12.7.1 Novartis Company Information
- 12.7.2 Novartis Business Overview
- 12.7.3 Novartis Revenue in Sustained-release Medicine Business (2021-2026)
- 12.7.4 Novartis Sustained-release Medicine Product Portfolio
- 12.7.5 Novartis Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Sustained-release Medicine Business (2021-2026)
- 12.8.4 Pfizer Sustained-release Medicine Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 China Res Double-Crane
- 12.9.1 China Res Double-Crane Company Information
- 12.9.2 China Res Double-Crane Business Overview
- 12.9.3 China Res Double-Crane Revenue in Sustained-release Medicine Business (2021-2026)
- 12.9.4 China Res Double-Crane Sustained-release Medicine Product Portfolio
- 12.9.5 China Res Double-Crane Recent Developments
- 12.10 Bayer
- 12.10.1 Bayer Company Information
- 12.10.2 Bayer Business Overview
- 12.10.3 Bayer Revenue in Sustained-release Medicine Business (2021-2026)
- 12.10.4 Bayer Sustained-release Medicine Product Portfolio
- 12.10.5 Bayer Recent Developments
- 12.11 AbbVie
- 12.11.1 AbbVie Company Information
- 12.11.2 AbbVie Business Overview
- 12.11.3 AbbVie Revenue in Sustained-release Medicine Business (2021-2026)
- 12.11.4 AbbVie Sustained-release Medicine Product Portfolio
- 12.11.5 AbbVie Recent Developments
- 12.12 AstraZeneca
- 12.12.1 AstraZeneca Company Information
- 12.12.2 AstraZeneca Business Overview
- 12.12.3 AstraZeneca Revenue in Sustained-release Medicine Business (2021-2026)
- 12.12.4 AstraZeneca Sustained-release Medicine Product Portfolio
- 12.12.5 AstraZeneca Recent Developments
- 12.13 Collegium Pharmaceutical, Inc
- 12.13.1 Collegium Pharmaceutical, Inc Company Information
- 12.13.2 Collegium Pharmaceutical, Inc Business Overview
- 12.13.3 Collegium Pharmaceutical, Inc Revenue in Sustained-release Medicine Business (2021-2026)
- 12.13.4 Collegium Pharmaceutical, Inc Sustained-release Medicine Product Portfolio
- 12.13.5 Collegium Pharmaceutical, Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst